Table 12 Key iPSC-based tumorigenesis case studies

“Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors” by Takahashi and Yamanaka, 2006

Demonstrated that adult cells could be reprogrammed to a pluripotent state, known as iPSCs, using only a few transcription factors

iPSCs have become a valuable tool for studying tumorigenesis as they can be differentiated into various cell types that can be used to model cancer progression and test potential therapies

[731]

“Modeling cancer using patient-derived induced pluripotent stem cells to understand development of childhood malignancies” by Navarro et al., 2018

Generated iPSCs from pediatric cancer patients to study the molecular mechanisms of cancer development

This study provided insight into the genetic and epigenetic changes that occur during cancer development and demonstrated the potential of iPSCs as a tool for personalized medicine

[15]

“Induced pluripotent stem cells as a tool for disease modelling and drug discovery in melanoma” by Castro-Pérez

et al., 2019

Used iPSCs to model melanoma progression and test potential drug therapies

The study highlighted the potential of iPSCs as a platform for drug discovery and personalized medicine in cancer treatment

[732]

“Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia” by Kotini et al., 2017

Generated iPSCs from patients with juvenile myelomonocytic leukemia (JMML) and identified disease-specific abnormalities in hematopoietic differentiation

The study provided insight into the cellular mechanisms underlying JMML and demonstrated the potential of iPSCs for studying rare diseases

[733]

“Induced pluripotent stem cells from human kidney epithelial cells reprogrammed with OCT4/SOX2/NANOG” by Montserrat et al., 2013

Generated iPSCs from human kidney epithelial cells and identified genes associated with renal cell carcinoma (RCC)

The study provided insight into the genetic changes that occur during RCC development and identified potential therapeutic targets for the disease

[535]

“Induced pluripotent stem cells in Huntington's disease: A review” by Chia et al., 2020

Reviewed the use of iPSCs to model Huntington's disease (HD) and identified potential therapeutic strategies

The study highlighted the potential of iPSCs as a tool for studying neurodegenerative diseases like HD and testing potential therapies

[611]

“Modeling breast cancer using patient-derived induced pluripotent stem cells to study tumor heterogeneity” by Lefort et al., 2022

Generated iPSCs from breast cancer patients and observed the heterogeneity of tumor cells in vitro

This study provided valuable insights into the clonal evolution and heterogeneity of breast cancer, contributing to a better understanding of its progression and potential therapeutic targets

[532]

“Induced pluripotent stem cells as a model for studying the role of oncogenic mutations in lung cancer” by Chen et al., 2017

Introduced specific oncogenic mutations into iPSCs derived from lung cells and observed their effect on cellular behavior and tumorigenic potential

The study revealed the impact of specific oncogenic mutations in driving lung cancer development and provided a platform for screening targeted therapies

[593]

“Induced pluripotent stem cell-based modeling of glioblastoma multiforme” by Plummer et al., 2019

Reprogrammed iPSCs from glioblastoma multiforme (GBM) patients and differentiated them into neural cells to study GBM pathogenesis

The research provided insights into the molecular mechanisms underlying GBM development and allowed for the testing of potential targeted therapies

[125]

“Using induced pluripotent stem cells to study the role of chromosomal rearrangements in leukemia” by Chao et al., 2017

Generated iPSCs from leukemia patients with specific chromosomal rearrangements and investigated their impact on leukemogenesis

This study provided valuable information on the role of chromosomal rearrangements in leukemia development and helped identify potential therapeutic targets

[593]

“Modeling colorectal cancer using patient-derived induced pluripotent stem cells to study tumor initiation and progression” by Crespo et al., 2017

Generated iPSCs from colorectal cancer patients and observed the initiation and progression of tumors in a controlled environment

This study provided insights into the early events of colorectal cancer development, including tumor initiation and progression, and identified potential therapeutic targets

[556]

“Induced pluripotent stem cell-based modeling of prostate cancer to study tumor-stromal interactions” by Buskin et al., 2021

Reprogrammed iPSCs from prostate cancer patients and co-cultured them with stromal cells to investigate tumor-stromal interactions

The research shed light on the complex interplay between tumor cells and the surrounding stromal microenvironment in prostate cancer and identified potential therapeutic strategies

[267]

“Modeling pancreatic ductal adenocarcinoma using induced pluripotent stem cells to study tumor heterogeneity and therapeutic resistance” by Kim et al., 2013

Generated iPSCs from pancreatic ductal adenocarcinoma (PDAC) patients and characterized the heterogeneity of PDAC tumors and their responses to therapies

This study enhanced our understanding of the complex nature of PDAC and provided insights into the mechanisms underlying therapeutic resistance in this challenging cancer type

[554]

“Modeling glioma development using patient-derived induced pluripotent stem cells to study tumor metabolism” by Martinez et al., 2016

Generated iPSCs from glioma patients and analyzed alterations in tumor metabolism pathways

This study provided insights into the metabolic rewiring occurring in glioma development, offering potential targets for therapeutic intervention

[533]